[Expression of MSI1 and HER2 in mammary Paget's disease and their correlation with clinicopathological features and prognosis]

Zhonghua Bing Li Xue Za Zhi. 2023 Aug 8;52(8):832-837. doi: 10.3760/cma.j.cn112151-20230214-00128.
[Article in Chinese]

Abstract

Objective: To investigate the expression of MSI1 and HER2 in mammary Paget's disease, and the correlation between the expression levels of MSI1 and HER2 and the clinicopathologic characteristics and prognosis of the patients. Methods: Clinical data and paraffin-embedded specimens of 34 pairs of mammary Paget's disease and underlying breast cancer were collected at the Department of Pathology, Affiliated Lianyungang Oriental Hospital of Xuzhou Medical University from March 2011 to December 2019. Immunohistochemistry was used to detect the expression of MSI1 and HER2 in mammary Paget's disease and the accompanying breast cancer, and to analyze the correlation between the expression levels of MSI1 and HER2 and their clinicopathologic features, as well as their influence on prognosis. Results: In mammary Paget's disease, the positive rate of MSI1 was 91.2% (31/34) and the positive rate of HER2 was 88.2% (30/34); the expression of MSI1 and HER2 was positively correlated (P=0.001, r=0.530). The expression of MSI1 was positively correlated with menopausal status (r=0.372, P=0.030) and lymph node metastasis (r=0.450, P=0.008). HER2 expression was positively correlated with menopausal status (r=0.436, P=0.010), and negatively correlated with ER expression (r=-0.365, P=0.034). The co-expression of MSI1 and HER2 was positively correlated with age (r=0.347, P=0.044) and menopausal status (r=0.496, P=0.003), and negatively correlated with ER expression (r=-0.461, P=0.006). Conclusions: MSI1 and HER2 are highly expressed in mammary Paget's disease and their expression levels are positively correlated. The correlation analysis between clinicopathological features and prognosis suggests that both of them may be involved in the occurrence and development of mammary Paget's disease and are potential therapeutic targets for mammary Paget's disease.

目的: 探讨MSI1和HER2在乳腺Paget病中的表达情况、表达水平及其与患者临床病理特征和预后的相关性。 方法: 收集徐州医科大学附属连云港市东方医院病理科2011年1月至2020年1月34对乳腺Paget病及下方伴发乳腺癌的临床资料及石蜡标本。采用免疫组织化学法检测MSI1和HER2在乳腺Paget病及下方伴发乳腺癌中的表达情况,分析二者表达水平的相关性及与临床病理特征的关系,并分析二者对预后的影响。 结果: 乳腺Paget病中,MSI1的阳性率为91.2%(31/34),HER2的阳性率为88.2%(30/34),二者表达呈正相关(P=0.001,r=0.530);MSI1的表达与绝经状态(r=0.372,P=0.030)、淋巴结转移(r=0.450,P=0.008)呈正相关;HER2表达与绝经状态(r=0.436,P=0.010)呈正相关,与雌激素受体(ER)表达(r=-0.365,P=0.034)呈负相关;MSI1与HER2的共表达与年龄(r=0.347,P=0.044)、绝经状态(r=0.496,P=0.003)呈正相关,与ER表达(r=-0.461,P=0.006)呈负相关。 结论: MSI1和HER2在乳腺Paget病中高表达,且二者表达水平呈正相关,临床病理特征和预后的相关性分析提示二者可能共同参与了乳腺Paget病的发生发展,是乳腺Paget病的潜在治疗靶点。.

Publication types

  • English Abstract

MeSH terms

  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Lymphatic Metastasis
  • Nerve Tissue Proteins / metabolism
  • Paget's Disease, Mammary* / diagnosis
  • Paget's Disease, Mammary* / metabolism
  • Paget's Disease, Mammary* / pathology
  • Prognosis
  • RNA-Binding Proteins

Substances

  • MSI1 protein, human
  • Nerve Tissue Proteins
  • RNA-Binding Proteins